Objective
In order to meet the expanding market for human stem cells (HSCs) in cell therapy, automated, cost-effective, large-scale manufacturing processes are required. AGLARIS Project is centered in the market launch of the patented AGLARIS BIOREACTOR for large-scale HSCs production, which perfectly meets the requirements for cell-based therapeutic products. Current bioreactors for HSCs producers consist in attempts to adapt bioreactors derived from traditional bioprocesses, but its use has not been widespread as they are not optimized for HSCs production. The automation level of bioreactors is limited to an initial quantity of 20M cells. As the cell sample from biopsies contains 0.5-1M cells, a previous manual cultivation is always required to reach the minimum quantity. This step affects cell quality. AGLARIS operates with the quantity of cells coming directly from biopsy, completely eliminating the manual pre-cultivation requirement. Moreover, current Bioreactors are limited to 300M cells per cell batch. The common are based on hollow-fibers as the substrate in which cells are anchored for growing. Once they reach its maximum capacity, cells need to be detached by using chemical and enzymatic reagents. AGLARIS operates in an iterative manner reaching 5000M cells without dividing the cultivation process in several batches. It is based on microcarriers which allows cell detachment by a simply small variation of temperature, avoiding adverse side effects. Additionally, for a complete disease management, the production of 600M cells on average is required. When produced manually, the cultivation of 600M cells can reach 9.347€, and by using hollow-fiber Bioreactors 15.643€. AGLARIS optimized culture process produces cell yields with the correct quality while using minimal amounts of expensive reagents, allowing the price to decrease to 1.015€ per 600 M of cells, meaning that costs will be reduced by up to 91% on average.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- engineering and technology mechanical engineering manufacturing engineering
- engineering and technology environmental biotechnology bioremediation bioreactors
- medical and health sciences medical biotechnology cells technologies stem cells
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering sensors
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
SG1 2FX Stevenage
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.